Clonal Expansion and Attenuated Apoptosis in Wilms' Tumors Are Associated with p53 Gene Mutations

Cancer Research

Volumn 55, Issue 2, 1995, Pages 215-219

  Bardeesy, Nabeel ^a   Beckwith, J Bruce ^c   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53;

ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; CHILDHOOD CANCER; GENE MUTATION; HUMAN; HUMAN TISSUE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0028850813     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855–4878, 1994.
2. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847–849, 1993.
3. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849–852, 1993.
4. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell, 74: 957–967, 1993.
5. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703–711, 1994.
6. Green, D. M. The diagnosis and management of Wilms' tumor. Sym. Ped. Oncol., 32: 735–754, 1985.
7. D'Angio, G. J., Breslow, N., Beckwith, J. B., Evans, A., Baum, E., DeLorimier, A., Fernbach, D., Hrabovsky, E., Jones, B., Kelalis, P., Othersen, B., Tefft, M., and Thomas, P. R. M. Treatment of Wilms' tumour. Results from the third National Wilms' tumour study. Cancer (Phila.), 64: 349–360, 1989.
8. Zuppan, C. W., Beckwith, J. B., and Luckey, D. W. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' tumor study pathology center. Hum. Pathol., 19: 1199–1209, 1988.
9. Bardeesy, N., Falkoff, D., Petruzzi, M-J., Nowak, N., Zabel, B., Adam, M., Aguiar, M. C., Grundy, P., Shows, T., and Pelletier, J. Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet., 7: 91–97, 1994.
10. Jackson, D. P., Hayden, J. D., and Quirke, P. Extraction of nucleic acid from fresh and archival material. In: M. J. McPherson, P. Quirke, and G. R. Taylor (eds.), PCR: A Practical Approach, pp. 29–50. Oxford, UK: Oxford University Press, 1991.
11. Sanger, A. F., Nicklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463–5467, 1977.
12. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol., 119: 493–501, 1992.
13. de Fromental, C. C., and Soussi, T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer, 4: 1–15, 1992.
14. Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavanee, W., and Vogelstein, B. Gonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (Lond.), 355: 846–847, 1992.
15. Wyllie, A. H. The biology of cell death. Anticancer Res., 5: 131–136, 1985.
16. Lowe, S., Jacks, T., Housman, D., and Ruley, H. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA, 91: 2026–2030, 1994.
17. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington, DC), 266: 807–810, 1994.
18. Lemoine, N. R., Hughes, C. M., and Cowell, J. K. Abberant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumors. J. Pathol., 168: 237–242, 1992.
19. Velasco, S., D'Amico, D., Schneider, N. R., Timmons, C., Chappell, E., Lee, D., and Nisen, P. D. Molecular and cellular heterogeneity of Wilms' tumor. Int. J. Cancer, 53: 672–679, 1993.
20. Malkin, D., Sexsmith, E., Yeger, H., Williams, B. R. G., and Coppes, M. J. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res., 54: 2077–2079, 1994.
21. Douglass, E. C., Look, T. A., Webber, B., Parham, D., Williams, J. A., Green, A. A., and Roberson, P. K. Hyperdiploidy and chromosomal rearrangements define the anaplastic variant of Wilms' tumor. J. Clin. Oncol., 4: 975–981, 1986.
22. Carder, P., Wyllie, A. H., Purdie, C. A., Morris, R. G., White, S., Piris, J., and Bird, C. C. Stabilized p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene, 8: 1397–1401, 1993.
23. Nowell, P. C. The clonal nature of neoplasia. Cancer Cells, 1: 29–33, 1989.
24. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds.), Current Protocols in Molecular Biology. New York: Greene Publishing Associates and John Wiley & Sons, 1993.